moxifloxacin has been researched along with itraconazole in 9 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (itraconazole) | Trials (itraconazole) | Recent Studies (post-2010) (itraconazole) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 249 | 4 | 108 |
| 3,157 | 552 | 1,690 | 6,440 | 653 | 2,357 |
| Protein | Taxonomy | moxifloxacin (IC50) | itraconazole (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 3.89 | |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 0.7 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 1.666 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.4256 | |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 0.2 | |
| C-X-C chemokine receptor type 1 | Homo sapiens (human) | 2.5676 | |
| Cruzipain | Trypanosoma cruzi | 3 | |
| Vasopressin V2 receptor | Homo sapiens (human) | 3.476 | |
| C-C chemokine receptor type 4 | Homo sapiens (human) | 3.2689 | |
| Lanosterol 14-alpha demethylase | Homo sapiens (human) | 3.6 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Guo, M; Li, C; Li, YR; Liu, JC; Piao, HR; Sun, LP; Zhang, TY; Zheng, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Piao, HR; Sun, LP; Wu, J; Zhang, TY; Zheng, CJ | 1 |
| Delesen, H; Moeller, JG; Nagelschmitz, J; Stass, H | 1 |
1 review(s) available for moxifloxacin and itraconazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for moxifloxacin and itraconazole
| Article | Year |
|---|---|
Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects.
Topics: Administration, Oral; Adolescent; Adult; Aza Compounds; Biological Availability; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Fluoroquinolones; Germany; Humans; Itraconazole; Male; Moxifloxacin; Quinolines | 2004 |
7 other study(ies) available for moxifloxacin and itraconazole
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Candida albicans; Drug Resistance, Multiple, Bacterial; Furans; Gram-Negative Bacteria; Gram-Positive Cocci; Ibuprofen; Indomethacin; Mice; Pyrazoles | 2015 |
Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents.
Topics: Anti-Bacterial Agents; Binding Sites; Cell Line; Cell Survival; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Protein Structure, Tertiary; Pyrazoles; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Triazines | 2019 |